ImmunityBio Announces Breakthrough Findings: ANKTIVA® Reverses Lymphopenia and Extends Survival in Advanced Lung Cancer Patients

Reuters

2025/09/08

ImmunityBio Announces Breakthrough Findings: ANKTIVA® Reverses Lymphopenia and Extends Survival in Advanced Lung Cancer Patients

ImmunityBio, Inc. has announced significant findings from the Phase 2 QUILT-3.055 study, highlighting the potential of ANKTIVA® (nogapendekin alfa inbakicept-pmln) in reversing lymphopenia and extending overall survival in patients with advanced non-small cell lung cancer (NSCLC) resistant to checkpoint inhibitor therapy. The study results, which were already presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona, reveal that ANKTIVA successfully reversed lymphopenia in 60% of participants, suggesting a promising approach to improving median overall survival. The Phase 3 ResQ201A trial is currently evaluating the combination of ANKTIVA and tislelizumab against docetaxel in second-line NSCLC patients. Interested patients can find more details at CSSIFM.org.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250908610169) on September 08, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2565681802"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565681802\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565681802?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565681802","market":"nz","top_or_hot":-1,"title":"ImmunityBio Announces Breakthrough Findings: ANKTIVA® Reverses Lymphopenia and Extends Survival in Advanced Lung Cancer Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunityBio Announces Breakthrough Findings: ANKTIVA® Reverses Lymphopenia and Extends Survival in Advanced Lung Cancer Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IBRX\">ImmunityBio, Inc.</a> has announced significant findings from the Phase 2 QUILT-3.055 study, highlighting the potential of ANKTIVA® (nogapendekin alfa inbakicept-pmln) in reversing lymphopenia and extending overall survival in patients with advanced non-small cell lung cancer (NSCLC) resistant to checkpoint inhibitor therapy. The study results, which were already presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona, reveal that ANKTIVA successfully reversed lymphopenia in 60% of participants, suggesting a promising approach to improving median overall survival. The Phase 3 ResQ201A trial is currently evaluating the combination of ANKTIVA and tislelizumab against docetaxel in second-line NSCLC patients. Interested patients can find more details at CSSIFM.org.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250908610169) on September 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio Announces Breakthrough Findings: ANKTIVA® Reverses Lymphopenia and Extends Survival in Advanced Lung Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio Announces Breakthrough Findings: ANKTIVA® Reverses Lymphopenia and Extends Survival in Advanced Lung Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-08 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunityBio Announces Breakthrough Findings: ANKTIVA® Reverses Lymphopenia and Extends Survival in Advanced Lung Cancer Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IBRX\">ImmunityBio, Inc.</a> has announced significant findings from the Phase 2 QUILT-3.055 study, highlighting the potential of ANKTIVA® (nogapendekin alfa inbakicept-pmln) in reversing lymphopenia and extending overall survival in patients with advanced non-small cell lung cancer (NSCLC) resistant to checkpoint inhibitor therapy. The study results, which were already presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona, reveal that ANKTIVA successfully reversed lymphopenia in 60% of participants, suggesting a promising approach to improving median overall survival. The Phase 3 ResQ201A trial is currently evaluating the combination of ANKTIVA and tislelizumab against docetaxel in second-line NSCLC patients. Interested patients can find more details at CSSIFM.org.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250908610169) on September 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL5XX0ZJ:1","article_id":"2565681802","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565681802","pubTimestamp":1757334700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ImmunityBio Announces Breakthrough Findings: ANKTIVA Reverses Lymphopenia and Extends Survival in Advanced Lung Cancer Patients. ImmunityBio, Inc. has announced significant findings from the Phase 2 QUILT-3.055 study, highlighting the potential of ANKTIVA  in reversing lymphopenia and extending overall survival in patients with advanced non-small cell lung cancer  resistant to checkpoint inhibitor therapy. The study results, which were already presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona, reveal that ANKTIVA successfully reversed lymphopenia in 60% of participants, suggesting a promising approach to improving median overall survival. The Phase 3 ResQ201A trial is currently evaluating the combination of ANKTIVA and tislelizumab against docetaxel in second-line NSCLC patients. Interested patients can find more details at CSSIFM.org.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc.","BK4139":"生物科技"},"translate_title":"ImmunityBio宣布突破性发现：ANKTIVA®逆转晚期肺癌患者淋巴细胞减少并延长生存期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"ImmunityBio Announces Breakthrough Findings: ANKTIVA® Reverses Lymphopenia and Extends Survival in Advanced Lung Cancer Patients\n    \n\nImmunityBio, Inc. has announced significant findings from the Phase 2 QUILT-3.055 study, highlighting the potential of ANKTIVA® (nogapendekin alfa inbakicept-pmln) in reversing lymphopenia and extending overall survival in patients with advanced non-small cell lung cancer (NSCLC) resistant to checkpoint inhibitor therapy. The study results, which were already presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona, reveal that ANKTIVA successfully reversed lymphopenia in 60% of participants, suggesting a promising approach to improving median overall survival. The Phase 3 ResQ201A trial is currently evaluating the combination of ANKTIVA and tislelizumab against docetaxel in second-line NSCLC patients. Interested patients can find more details at CSSIFM.org.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250908610169) on September 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}